Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ivan Antonevich

Interventional Pain Medicine New Hartford, NY Medical Doctor

NPI 1043256118 CMS profile 228068

1729 Burrstone Rd, New Hartford, NY 13413

Open in the dashboard

General payments

$12,751

482 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ivan Antonevich of New Hartford, NY is reported in the CMS Open Payments database as having received $12,751 across 482 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,727 72
2024 General $2,128 104
2023 General $1,679 87
2022 General $3,434 87
2021 General $800 42
2020 General $549 28
2019 General $2,434 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ivan Antonevich
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Ivan Antonevich were reported at $1,727. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Ivan Antonevich Interventional Pain Medicine median Middle half National median
2019 $2,434 $684 $216–$2,079 $163
2020 $549 $382 $122–$1,109 $114
2021 $800 $552 $167–$1,554 $132
2022 $3,434 $605 $187–$1,924 $149
2023 $1,679 $671 $195–$1,915 $160
2024 $2,128 $684 $206–$1,837 $164
2025 $1,727 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,470 118 payments
  2. Boston Scientific Corporation $2,229 95 payments
  3. Medtronic USA, Inc. $2,040 39 payments
  4. AbbVie, Inc. $2,030 89 payments
  5. Allergan Inc. $325 21 payments
  6. SI-BONE, Inc. $325 2 payments
  7. Medtronic, Inc. $247 14 payments
  8. Pfizer Inc. $240 13 payments
  9. Nevro Corp. $165 8 payments
  10. Ipsen Biopharmaceuticals, Inc $155 8 payments
  11. Other $1,524 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,442 474 payments
  2. Travel and Lodging $2,280 7 payments
  3. Education $29 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS $1,940 30 payments
  2. PROCLAIM Neuromodulation $1,758 27 payments
  3. BOTOX Botox Therapeutic $1,628 70 payments
  4. WaveWriter Alpha Prime 16 $1,463 52 payments
  5. BOTOX Hyperhydrosis $607 35 payments
  6. PROCLAIM Neuromodulation $542 26 payments
  7. PROCLAIM Neuromodulation $361 32 payments
  8. SPECTRA WAVEWRITER $244 9 payments
  9. QULIPTA $230 8 payments
  10. PROCLAIM Structural Heart $201 13 payments
  11. Other $4,102 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$242,061

Of which drugs: $11,337

Medicare patients

314

Average age 73

Services billed

9,293

189 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Diabetes 36%
Ischemic heart disease 31%
Depression 27%
COPD 25%
Chronic kidney disease 23%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 238 5,584 $4,275
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 25 224 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $588
$588 — —
QULIPTA
  • AbbVie, Inc. $59
$59 — —
UBRELVY
  • AbbVie, Inc. $51
$51 — —
NURTEC ODT
  • PFIZER INC. $47
$47 — —
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

482 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record